top of page
  • LinkedIn

Our Story

We aim to shift the current wound care treatment paradigm with a high impact therapeutic approach

For decades, innovation in the wound care industry has been dominated by incremental, low-risk and device-driven innovations

Only one new pharmaceutical treatment approved for use - 20 years ago

Despite this plethora of new products, healing rates have barely changed

The FDA & industry is calling for a new approach

We aim to shift the current treatment paradigm with a high impact therapeutic approach to debridement

We aim to enable dramatic improvements in healing rates and patients’ quality of life

Our Mission

Significantly improving the health and wellbeing of patients with chronic wounds

shutterstock_1682324479.jpg

About Us

Promoting safe and effective debridement & wound bed preparation

Executive Team

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.40.png
Screenshot 2024-06-09 at 16.18.17.png

Andy Weymann, MD

CHAIRMAN

A surgeon by background and formerly Chief Medical Officer at Smith & Nephew, Andy brings not only deep sector experience to SolasCure, but also more than 25 years of executive and board experience in global medical device, biopharma & regenerative medicine companies to SolasCure.

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.17.png

Lee Harle

CHIEF EXECUTIVE OFFICER

Lee is an experienced business leader with >25 years of experience building businesses & joint-ventures in consumer goods, technology and life-science industries around the world, specialising in life-science venture building and commercialisation. Formerly Chief Business Officer at SolasCure.

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.31.png
Screenshot 2024-06-09 at 16.18.17.png

David Fairlamb

Chief Development Officer

David brings vast, global knowledge of wound care development and Regulatory Affairs, with over 30 years of experience across Drug, Biologics, Medical Devices and Combination Products, including senior regulatory positions within Smith & Nephew Wound Management, Renovo plc and in consultancy at ProTherax Ltd.

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.11.png
Screenshot 2024-06-09 at 16.18.17.png

Dr. Bela Kelety

CHIEF TECHNOLOGY OFFICER

Bela brings a long track record of successful R&D and technology development to Solascure with experience across multiple bioscience companies, including  BRAIN AG. Bela previously co-founded a successful biotech company and has a Ph.D. in biochemistry from the Max Planck Institute.

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.17.png
Screenshot 2024-06-09 at 16.18.17.png

Oliver Schofield

CHIEF FINANCIAL OFFICER

Oliver is an experienced biotech startup CFO having started his career in Management Consulting at KPMG. Oliver is a CIMA certified accountant with an MPhil in Bioscience Enterprise from the University of Cambridge.

Screenshot 2024-06-09 at 16.17.56.png
Screenshot 2024-06-09 at 16.18.24.png
Screenshot 2024-06-09 at 16.18.17.png

Antoinette van Dijk, MD

DIRECTOR CLINICAL AND MEDICAL AFFAIRS

With more than 20 years of both strategic and operational experience in clinical research and development of pharmaceuticals and medical devices, Antoinette brings a deep understanding of the complexity and practicalities of global clinical development to Solascure, leveraging her experience across the CRO and Pharma industries together with a focus on methodological and ethical aspects of development.

Screenshot 2024-06-09 at 16.17.56.png
449676356_371580378934325_3423199155430850846_n.jpg
Screenshot 2024-06-09 at 16.18.17.png

Adam Rytko

Quality Assurance Director

Adam has over 18 years of experience in the pharmaceutical and clinical environment with emphasis in Quality Assurance and auditing. Starting as a CRA he shifted to GCP Quality area, focusing on clinical site and vendor auditing, executing approx. 200 audits. For 5 years Adam is in charge of quality systems implementation and development.

Board Of Directors

Screenshot 2024-06-09 at 16.18.40.png

Andy Weymann

M.D.

Chairman

A surgeon by background and formerly Chief Medical Officer at Smith & Nephew, Andy brings not only deep sector experience, but also more than 25 years of executive and board experience in global medical device, biopharma & regenerative medicine companies to SolasCure.

François Fournier

Director

CEO & President of HTL Biotechnology

Former Head of Smith & Nephew Wound Care in US and Asia, CEO of Virbac Corp., held multiple leadership roles at Nestlé Skin Health & Abbott.

Riad Armanious

Director

CEO of Eva Pharma

Vice Chairman Egyptian Industrial Chamber of Pharmaceuticals, active in “T20” foundation and YPO (Young Presidents Association).

Adriaan Moelker

Director

CEO of BRAIN Biotech AG

Previously held a variety of management positions during his 35-year career with a particular focus on enzymes and biotechnology.

Dan Wright

Director

Highly Experienced Board

Level Executive of public and private companies. He was previously founding partner at NorthEdge Capital, following an investment career at Callahan Associates, Deutsche Bank and RBS.

Jane Hart

Director

VP Clinical Operations at LunaBridge

Leader in drug and device research, with more than 25 years of experience in the clinical research industry, including serving as Vice President, Global Clinical Development at 3M.

Frank Goebel

Director

Former CFO of BRAIN Biotech AG and co-CEO at SymbioPharm

Frank brings long executive experience in bio-based industries to SolasCure. Prior experience at RBS and ING.

Key Medical Advisors

Transforming Chronic Wound Patient Outcomes

Empowering Clinicians with Practical, Impactful Solutions 

Enhancing Efficiency & Value for Health Systems

Get in touch with us

By submitting this message I consent to share my name and email address with SolasCure

Robert.jpg

Robert Kirsner

M.D., PhD

Key Opinion Leader

Dr. Robert Kirsner, M.D., PhD is Chairman and Harvey Blank Professor of Dermatology at the University of Miami Miller School of Medicine. He directs the University of Miami Hospital Wound Center and serves as Chief of Dermatology at University of Miami Hospital and Clinics. Dr. Kirsner earned his MD and PhD from the University of Miami and has published over 550 articles.